Skip to content
thestock.space

Vineet Laboratories (VINEETLAB) had a P/E of 15.2× on 6 Nov 2026, below the industry P/E of 18.2×, and the shares are 22% below their 52-week high. It earns ROCE of 11% and ROE of 3.7%, and sales and net profit fell 35% and 3.9% a year over 3 years. Debt is 0.99× equity. It is a small-cap company with a market cap of ₹71 Cr, ranked 63rd of 76 Chemicals companies by market cap; the shares fell 21% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹37.69
Day high
₹37.69
Day low
₹35.87
Prev. close
₹37.08
Volume
2.2 L

Health check

1 good · 2 fair · 3 to check
  • ReturnsIn line

    −21.4% over a year, better than 3 of 7 peers.

  • Price tagCheaper

    P/E 15.2 vs industry 18.2.

  • GrowthShrinking

    Sales −34.6%, profit −3.9% a year over 3 years.

  • ProfitabilityAverage

    ROCE 10.7% vs peer median 10.6%.

  • Balance sheetStretched

    Debt 0.99× equity, interest covered 1.3×, Piotroski 4 of 9.

  • Red flags3 to check

    Return on equity is low at 3.7%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Chemicals

75 listed peers. Screen the industry

Small cap

₹71 Cr, #63 of 76 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹63 Cr · profit ₹3 Cr
Market cap
₹71 Cr
Small cap
P/E
15.2
Industry 18.2
Price to book
1.37
Peers 2.62
Dividend yield
0.00%
ROE
3.7%
Peers 11.7%
ROCE
10.7%
Peers 10.6%
Debt to equity
0.99
Debt ₹45 Cr
EPS (TTM)
₹2.44
Face value ₹10
OPM (TTM)
16.7%
Net margin 5.6%
Sales growth
+39.6%
Latest quarter vs a year ago
Profit growth
n/a
Year-ago quarter not reported
Price to sales
1.14
EV/EBITDA 9.9

Strengths and risks

Strengths

  • Quarterly sales up 39.6% on a year ago.

Risks to check

  • Return on equity is low at 3.7%.
  • Interest coverage of only 1.7×.
  • Promoter stake down from 12.5% to 6.0%.

Derived automatically from reported figures. Not a recommendation.

About Vineet Laboratories

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium,…

Headquarters
Hyderabad
Sector
Basic Materials
ISIN
INE505Y01010
Website
vineetlabs.co.in

Price range

52 weeks

₹27.96₹47.39

Today

₹35.87₹37.69
Avg volume (3M)
1.1 L
1-year return
minus 21.4%
From 52-week high
minus 21.8%

Peers · Chemicals

Capital-heavy industry columns

Compare with peersScreen the whole industry
Company
NAVINFLUORNavin Fluorine International9,010.00plus 1.87%46,25050.842.718.7%34.3%0.2816.5%plus 46.1%
DEEPAKNTRDeepak Nitrite1,533.60minus 0.67%20,91719.722.310.8%18.0%0.27−0.5%minus 11.9%
TATACHEMTata Chemicals607.45minus 1.36%15,475–12.4−3.0%12.2%0.36−4.8%minus 31.0%
DEEPAKFERTDeepak Fertilisers & Petrochemicals Corp.1,155.30minus 0.69%14,59914.811.511.2%17.6%0.762.6%minus 22.7%
RPELRaghav Productivity Enhancers1,780.80plus 0.95%8,178116.0107.1–29.9%0.0223.5%plus 95.4%
GNFCGujarat Narmada Valley Fertilizers and Chemicals451.80minus 1.87%6,6396.35.410.4%14.8%0.01−8.8%minus 7.2%
ACIArchean Chemical Industries416.40minus 1.95%5,14151.323.27.7%20.0%0.28−9.2%minus 34.6%
VINEETLABVineet Laboratories37.04minus 0.11%7115.211.710.7%16.7%0.99−34.6%minus 21.4%
Median of 7 peers–−0.69%14,59935.222.310.6%18.0%0.28−0.5%−11.9%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
7.417.415.618.910.4
7.114.213.216.48.1
0.33.22.52.52.2
4.3%18.2%15.9%13.2%21.6%
00000.1
0.62.21.111
0.60.60.60.50.6
−0.90.40.810.8
3.9%−7.9%−4.0%27.1%−92.7%
−0.90.40.90.71.5
-0.940.360.920.430.73

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
−34.6%
Profit CAGR 3Y
−3.9%
EPS CAGR 3Y
−4.4%
ROE
3.7%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2121517559.4
–minus 29.1%minus 50.2%minus 20.8%
20414391.350.9
87.2−16.38.5
3.8%4.8%−21.7%14.3%
−0.9−0.90.10.1
2.73.844.9
2.42.52.52.4
−00.41.9–
20.4−20.81.3
38.3%−182.6%2.8%13.4%
1.31−20.21.1
–minus 18.0%minus 2065.8%–
1.140.93-20.891.00

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
9.29.29.219.2
24.525.55.426.4
31.144.34045.3
51.137.839.833.9
11611794.5125
26.626.925.524.2
0.10.20.21
0.60.20.317.1
88.489.568.682.4
11611794.5125

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−9.6−6.611.5−12
−6.7−2.2−3.2−1.1
0.38.4−8.229.7
−16−0.40.116.6
−7.6−2.8−1−1.2
−17.3−9.410.4−13.2
−0.9–––

Shareholding pattern

Source: NSE filings
6.0%
promoters
  • Promoters5.98%
  • Public94.02%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 20265.98%94.02%0.00
30 Jun 20265.98%94.02%0.00
31 Mar 20265.98%94.02%0.00
2 Feb 20265.98%94.02%minus 6.48
31 Dec 202512.46%87.54%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you